Fig. 2.

The IMM01 efficacy in combination with PD-L1 mAb (KN035) (A) and PD-L1 mAb (Tislelizumab) (B) on the in-house developed CT26-hPDL1(Tg) hCD47(Tg)mPDL1(KO)mCD47(KO) cell mouse tumor models, with CD33 mAb (Gemtuzumab) on HL-60 xenograft tumor model (C) and Her2 mAb (Inetetamab) on SNU-1 xenograft tumor model (D). It demonstrated that the combination of IMM01 with PD-1 or PD-L1 antibody resulted in significantly stronger antitumor effects than PD-1 or PD-L1 alone (A, B). The efficacy of IMM01 alone and in combination with CD33 mAb and HER-2 mAb in the SNU-1 and HL-60 xenograft models (C, D), respectively, revealed great therapeutic potential in combination with these mAbs